Chemotherapy in the belly for pancreatic cancer that has spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your pancreatic cancer must have spread to the lining of your abdomen (peritoneum) but not to other organs.
- You must have been on chemotherapy (FOLFIRINOX or NALIRIFOX) for 0 to 4 months and be able to take more.
- You need to be in fairly good health, able to do daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function must be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PIPAC, where chemotherapy is sprayed as a mist into the abdomen during a minimally invasive surgery. It is for people whose pancreatic cancer has spread to the lining of the belly, and aims to see if this approach is safe and helpful.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) is effective as a first treatment for pancreatic cancer that has spread. It also studies how gut bacteria affect the success of a second treatment with gemcitabine and paclitaxel. The goal is to find better ways to treat pancreatic cancer by personalizing therapy.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This Phase 2 study tests a treatment that warms chemotherapy and delivers it directly into the abdomen to treat pancreatic cancer that has spread to the lining of the belly (peritoneum). You may be eligible if you completed earlier chemotherapy and your body shows signs the cancer is responding, with limited spread in the abdomen.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.